Click here to read the articles and download the PDF
How Tariffs Could Affect Generic Drug Prices and the Global Pharmaceutical Market
February 6th 2025In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jim Shehan, chair of the FDA Regulatory practice at Lowenstein Sandler, describes what the approach of pharma companies should be amid the latest/pending tariffs imposed on Canada, Mexico, and China, along with their potential impact on the pharma supply chain.
Strengthening Production Efforts Domestically
February 4th 2025In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Alex Guillen, global pharma and life sciences director at Tive, explains what needs to be done in the United States in order to increase manufacturing output.
Analyzing Supply Chain Complexities
February 3rd 2025In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Alex Guillen, global pharma and life sciences director at Tive, describes the highlights of a recent pharma supply chain security and visibility report that his company released.
FDA Approves Actemra Biosimilar
January 31st 2025Celltrion’s Avtozma has been indicated for the treatment of giant cell arteritis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and COVID-19—in the same dosages and formulations as its tocilizumab reference product.
What Round II of Medicare Part D Drug Prices Signify for the Pharma Industry
January 30th 2025In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, value & access advisor for Schoonveld Advisory and author of The Price of Global Health, comments on the future implications of the latest CMS drug price negotiations.